World Children's Transplant Fund: "When the children of our world die needlessly and without hope, a piece of us dies with them whether we know it or not. And when we help just one to live, we find a small piece of immeasurable, indescribably joy." -- Mark A. Kroeker, Founder, WCTF

 

 

 
Home
New Initiatives
Mission
Board Members
Founder's Message
How To Help
Amela & Veronica
WCTF Locations
Awards
Contact
Links & News

 

WCTF.org Transplant News

Transplant news, links, and other general medical news -- updated regularly.


Thursday, May 8, 2008

 

Novadaq Technologies Notice of Annual Meeting

Novadaq Technologies Notice of Annual Meeting

TORONTO, May 8 /PRNewswire-FirstCall/ -- Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of real-time imaging and image guidance systems for use in the operating room, will be holding its annual meeting, hosted by Dr. Arun Menawat, President and Chief Executive Officer and Mr. Roger Deck, Chief Financial Officer.

DATE: May 15, 2008

TIME: 9:30 am, Eastern Daylight Time

LOCATION: Saint Andrews Club
150 King Street West
27th Floor
(Northeast Corner of University & King)
Toronto, Ontario, Canada

WEBCAST: A live audio webcast of the call will be available at

www.novadaq.com

Webcast attendees are welcome to listen to the
conference in real-time or on-demand at your
convenience. The webcast will be archived for 90 days.

Please connect to this website at least 15 minutes
prior to the conference call to ensure adequate time
for any software download that may be needed to hear
the webcast.

About Novadaq Technologies

Novadaq Technologies Inc. commercializes real-time imaging and image guidance systems for use in the operating room. With one set of proprietary core technologies, Novadaq's products have multiple applications. Novadaq's SPY System enables cardiac surgeons to diagnose intra-operatively by visually assessing coronary vasculature and bypass graft functionality during the course of heart bypass surgery. The SPY System is also indicated for use during other surgeries, such as cardiovascular, plastic, reconstructive, organ transplant and urological procedures. SPY can be used to visualize blood vessels, tumors, tumor margins and the lymphatic system. Novadaq introduced PINPOINT, its first minimally invasive imaging system for autofluorescence in October 2007. PINPOINT allows surgeons to differentiate between healthy and cancerous tissue in the lung and other hollow organs. Further expanding its portfolio of minimally invasive products, Novadaq is developing SPYscope which combines the typical features of a standard endoscope with the additional capabilities of SPY imaging. Novadaq is the exclusive United States distributor of PLC Medical's CO2 HEART LASER System, used in the same cardiac procedures as the SPY System. Novadaq also offers the OPTTX(R) System, which leverages the company's core imaging technology and is designed for the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD). For more information, please visit the company's website at www.novadaq.com.

Forward looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT and the SPY System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Source: Novadaq Technologies Inc.

CONTACT: visit our website at www.novadaq.com, or contact: Arun Menawat,
PhD, MBA, President & CEO, Novadaq Technologies Inc., (905) 629-3822 x 202,
amenawat@novadaq.com; Michael Moore, Investor Relations, The Equicom Group,
(416) 815-0700 x 241, mmoore@equicomgroup.com


-------
Profile: Transplant News


Archives

Mar 21, 2008   Mar 22, 2008   Mar 23, 2008   Mar 24, 2008   Mar 25, 2008   Mar 26, 2008   Mar 27, 2008   Mar 28, 2008   Mar 29, 2008   Mar 30, 2008   Mar 31, 2008   Apr 1, 2008   Apr 2, 2008   Apr 3, 2008   Apr 4, 2008   Apr 5, 2008   Apr 6, 2008   Apr 7, 2008   Apr 8, 2008   Apr 9, 2008   Apr 10, 2008   Apr 11, 2008   Apr 12, 2008   Apr 13, 2008   Apr 14, 2008   Apr 15, 2008   Apr 16, 2008   Apr 17, 2008   Apr 18, 2008   Apr 19, 2008   Apr 20, 2008   Apr 21, 2008   Apr 22, 2008   Apr 23, 2008   Apr 24, 2008   Apr 25, 2008   Apr 26, 2008   Apr 27, 2008   Apr 28, 2008   Apr 29, 2008   Apr 30, 2008   May 1, 2008   May 2, 2008   May 3, 2008   May 4, 2008   May 5, 2008   May 6, 2008   May 7, 2008   May 8, 2008  

Subscribe to Posts [Atom]

 

 


Copyright © 2006 World Children's Transplant Fund
Privacy Policy | Contact | Site Map | Transplant News